Glaukos logo
Glaukos
GKOS | NYSE
Chart Builder DCF Calculator
$244.88
-$0.84 (-0.34%)
At close: Nov 16, 2026, 4:00 PM ET
$246.00
+$1.12 (+0.46%)
After-hours: Nov 16, 2026, 7:33 PM ET

Glaukos Company Profile

Company profile explained

Company Profile

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

Key Executives

Name Position
Thomas William Burns Chairman & Chief Executive Officer
Alex R. Thurman Senior Vice President & Chief Financial Officer
Joseph E. Gilliam President & Chief Operating Officer
Christopher William Lewis Vice President of Investor Relations & Corporate Affairs
Diana A. Scherer Vice President of Compliance & Deputy General Counsel
L. Jay Katz FACS Chief Medical Officer
Michele Allegretto Senior Vice President of Human Resources
Robert L. Davis Senior Vice President, General Counsel & Business Development
Tomas Navratil Chief Development Officer
Tracy Founds Senior Vice President of Global Quality & Medical Safety

Latest SEC Filings

Date Type Title
Oct 28, 2026 10-Q Quarterly Report
Oct 28, 2026 8-K Current Report
Oct 07, 2026 4 Filing
Sep 28, 2026 4 Filing
Sep 18, 2026 4 Filing
Sep 01, 2026 4 Filing
Aug 20, 2026 4 Filing
Aug 13, 2026 4 Filing
Aug 11, 2026 4 Filing
Aug 03, 2026 4 Filing
View All SEC Filings ➞
Glaukos
Glaukos logo
Country United States
IPO Date Jun 25, 2015
Industry Medical - Devices
Sector Healthcare
Employees 1,094
CEO Thomas William Burns

Contact Details

One Glaukos Way Aliso Viejo, California 92656 United States

Stock Details

Ticker Symbol GKOS
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001192448
CUSIP Number 377322102
ISIN Number US3773221029
SIC Code 3841

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.